|
|
|
|
|
|
Early, Late, PrEP, PEP |
Covid Analysis (Preprint) (meta analysis) |
meta-analysis |
Metformin for COVID-19: real-time meta analysis of 39 studies |
|
Details
• Statistically significant improvements are seen for mortality, ventilation, and hospitalization. 23 studies from 22 independent teams in 8 different countries show statistically significant improvements in isolation (20 for the most ser.. |
|
Details
Source
PDF
Early, Late, PrEP, PEP
Early, Late, PrEP, PEP
|
| Metformin for COVID-19: real-time meta analysis of 39 studies |
| Covid Analysis (Preprint) (meta analysis) |
• Statistically significant improvements are seen for mortality, ventilation, and hospitalization. 23 studies from 22 independent teams in 8 different countries show statistically significant improvements in isolation (20 for the most serious outcome).• Meta analysis using the most serious outcome reported shows 27% [20‑33%] improvement. Results are similar for Randomized Controlled Trials, similar after exclusions, and similar for peer-reviewed studies. Clinical outcomes suggest benefit while viral and case outcomes do not, consistent with an intervention that aids recovery but is not antiviral. • Results are robust — in exclusion sensitivity analysis 27 of 39 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.• Most studies analyze existing use with diabetic patients. Many results are subject to confounding by indication — metformin is typically used early in the progression of type 2 diabetes. Prophylaxis results typically include continuing use after infection and hospitalization, and greater benefit is seen for more serious outcomes. The beneficial effect of metformin may be more related to later stages of COVID-19. The TOGETHER RCT shows 27% lower mortality. While not statistically significant, p = 0.53, this is consistent with the mortality results from all studies, 33% [25‑40%].• While many treatments have some level of efficacy, they do not replace vaccines and other measures to avoid infection. None of the metformin studies show zero events in the treatment arm.Multiple treatments are typically used in combination, and other treatments are more effective.• No treatment, vaccine, or intervention is 100% available and effective for all variants. All practical, effective, and safe means should be used. Denying the efficacy of treatments increases mortality, morbidity, collateral damage, and endemic risk.• All data to reproduce this paper and sources are in the appendix. Other meta analyses for metformin can be found in [Hariyanto, Kow, Lukito, Yang], showing significant improvements for mortality and progression.
![]()
Covid Analysis et al., 5/24/2022, preprint, 1 author.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
MacFadden et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156 |
cases, ↓1.0%, p=0.45 |
Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications |
|
Details
Retrospective 26,121 cases and 2,369,020 controls ≥65yo in Canada, showing no significant differences in cases with chronic use of metformin. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications |
| MacFadden et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156 |
|
Retrospective 26,121 cases and 2,369,020 controls ≥65yo in Canada, showing no significant differences in cases with chronic use of metformin.
|
risk of case, 1.0% lower, OR 0.99, p = 0.45, RR approximated with OR.
|
![]()
MacFadden et al., 3/29/2022, retrospective, Canada, North America, peer-reviewed, 9 authors, study period 15 January, 2020 - 31 December, 2020.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Wong et al., Frontiers in Endocrinology, doi:10.3389/fendo.2022.810914 |
death, ↓59.0%, p=0.01 |
Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort |
|
Details
Retrospective 1,214 COVID+ type 2 diabetes patients in Hong Kong, showing lower mortality and improved recovery with metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort |
| Wong et al., Frontiers in Endocrinology, doi:10.3389/fendo.2022.810914 |
|
Retrospective 1,214 COVID+ type 2 diabetes patients in Hong Kong, showing lower mortality and improved recovery with metformin use.
|
risk of death, 59.0% lower, OR 0.41, p = 0.01, treatment 786, control 428, adjusted, propensity score weighting, multivariable, RR approximated with OR.
|
|
risk of no recovery, 60.6% lower, OR 0.39, p = 0.005, treatment 786, control 428, adjusted, propensity score weighting, multivariable, RR approximated with OR.
|
|
clinical improvement, 63.5% better, OR 0.36, p = 0.009, treatment 786, control 428, adjusted, propensity score weighting, multivariable, RR approximated with OR.
|
|
risk of no hospital discharge, 55.8% lower, OR 0.44, p = 0.009, treatment 786, control 428, adjusted, propensity score weighting, multivariable, RR approximated with OR.
|
![]()
Wong et al., 3/7/2022, retrospective, China, Asia, peer-reviewed, 11 authors, study period 21 January, 2020 - 31 January, 2021.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Wong et al., Diabetes Care, doi:10.2337/dc21-2186 |
death, ↓51.0%, p<0.0001 |
Glycemic Control and Clinical Outcomes in U.S. Patients With COVID-19: Data From the National COVID Cohort Collaborative (N3C) Database |
|
Details
N3C retrospective 39,616 COVID-19 patients with diabetes in the USA, showing lower mortality, ventilation, and hospitalization with metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Glycemic Control and Clinical Outcomes in U.S. Patients With COVID-19: Data From the National COVID Cohort Collaborative (N3C) Database |
| Wong et al., Diabetes Care, doi:10.2337/dc21-2186 |
|
N3C retrospective 39,616 COVID-19 patients with diabetes in the USA, showing lower mortality, ventilation, and hospitalization with metformin use.
|
risk of death, 51.0% lower, HR 0.49, p < 0.001, treatment 10,408, control 29,208, Cox proportional hazards.
|
|
risk of mechanical ventilation, 41.0% lower, OR 0.59, p < 0.001, treatment 10,408, control 29,208, adjusted, multivariable, RR approximated with OR.
|
|
risk of hospitalization, 40.0% lower, OR 0.60, p < 0.001, treatment 10,408, control 29,208, adjusted, multivariable, RR approximated with OR.
|
![]()
Wong et al., 2/24/2022, retrospective, USA, North America, peer-reviewed, 15 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Usman et al., Journal of Thrombosis and Thrombolysis, doi:10.1007/s11239-022-02631-7 |
death, ↓59.8%, p=0.21 |
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes |
|
Details
Retrospective 75 diabetes patients, 34 on metformin, showing improved clinical outcomes with treatment, without statistical significance. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes |
| Usman et al., Journal of Thrombosis and Thrombolysis, doi:10.1007/s11239-022-02631-7 |
|
Retrospective 75 diabetes patients, 34 on metformin, showing improved clinical outcomes with treatment, without statistical significance.
|
risk of death, 59.8% lower, RR 0.40, p = 0.21, treatment 3 of 34 (8.8%), control 9 of 41 (22.0%), NNT 7.6.
|
|
risk of mechanical ventilation, 75.9% lower, RR 0.24, p = 0.05, treatment 2 of 34 (5.9%), control 10 of 41 (24.4%), NNT 5.4.
|
|
hospitalization time, 33.7% lower, relative time 0.66, p = 0.13, treatment 34, control 41.
|
![]()
Usman et al., 1/18/2022, retrospective, USA, North America, peer-reviewed, 10 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Ojeda-Fernández et al., Diabetes, Obesity and Metabolism, doi:10.1111/dom.14648 |
death, ↓16.2%, p<0.0001 |
Metformin use is associated with a decrease in risk of hospitalization and mortality in COVID-19 diabetic patients: a population-based study in Lombardy |
|
Details
Retrospective 31,966 COVID+ patients using anti-hyperglycemic drugs in Italy, showing lower mortality and ICU admission with metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin use is associated with a decrease in risk of hospitalization and mortality in COVID-19 diabetic patients: a population-based study in Lombardy |
| Ojeda-Fernández et al., Diabetes, Obesity and Metabolism, doi:10.1111/dom.14648 |
|
Retrospective 31,966 COVID+ patients using anti-hyperglycemic drugs in Italy, showing lower mortality and ICU admission with metformin use.
|
risk of death, 16.2% lower, RR 0.84, p < 0.001, treatment 1,476 of 6,556 (22.5%), control 1,787 of 6,556 (27.3%), NNT 21, OR converted to RR, propensity score matching.
|
|
risk of death, 22.1% lower, RR 0.78, p < 0.001, treatment 968 of 6,556 (14.8%), control 1,261 of 6,556 (19.2%), NNT 22, OR converted to RR, in-hospital mortality, propensity score matching.
|
|
risk of ICU admission, 22.4% lower, RR 0.78, p = 0.01, treatment 166 of 6,556 (2.5%), control 212 of 6,556 (3.2%), NNT 143, OR converted to RR, propensity score matching.
|
|
risk of hospitalization, 2.7% lower, RR 0.97, p = 0.11, treatment 3,551 of 6,556 (54.2%), control 3,670 of 6,556 (56.0%), NNT 55, OR converted to RR, propensity score matching.
|
|
risk of death, 8.3% lower, RR 0.92, p = 0.06, treatment 793 of 3,297 (24.1%), control 876 of 3,297 (26.6%), NNT 40, OR converted to RR, excluding patients previously treated with insulin, propensity score matching.
|
|
risk of death, 16.0% lower, RR 0.84, p = 0.003, treatment 512 of 3,297 (15.5%), control 618 of 3,297 (18.7%), NNT 31, OR converted to RR, excluding patients previously treated with insulin, in-hospital mortality, propensity score matching.
|
|
risk of ICU admission, 39.2% lower, RR 0.61, p = 0.002, treatment 64 of 3,297 (1.9%), control 102 of 3,297 (3.1%), NNT 87, OR converted to RR, excluding patients previously treated with insulin, propensity score matching.
|
|
risk of hospitalization, 2.2% higher, RR 1.02, p = 0.36, treatment 1,822 of 3,297 (55.3%), control 1,792 of 3,297 (54.4%), OR converted to RR, excluding patients previously treated with insulin, propensity score matching.
|
![]()
Ojeda-Fernández et al., 1/10/2022, retrospective, Italy, Europe, peer-reviewed, 11 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Wallace et al., BMJ Open, doi:10.1136/bmjopen-2021-050051 |
death, ↓72.0%, p<0.0001 |
Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study |
|
Details
Retrospective 9,532 hospitalized COVID+ veterans in the USA, showing lower mortality with metformin use. The study provides results for use before, after, and before+after. Before+after should more accurately represent prophylaxis up to C.. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study |
| Wallace et al., BMJ Open, doi:10.1136/bmjopen-2021-050051 |
|
Retrospective 9,532 hospitalized COVID+ veterans in the USA, showing lower mortality with metformin use. The study provides results for use before, after, and before+after. Before+after should more accurately represent prophylaxis up to COVID-19 infection (and continued use). Before included use up to 2 years before, and after included use up to 60 days later.
|
risk of death, 72.0% lower, HR 0.28, p < 0.001, treatment 103 of 1,203 (8.6%), control 1,536 of 6,970 (22.0%), NNT 7.4, adjusted, before+after, propensity score weighting, Cox proportional hazards.
|
![]()
Wallace et al., 12/31/2021, retrospective, database analysis, USA, North America, peer-reviewed, 6 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Al-Salameh et al., Diabetes & Metabolism, doi:10.1016/j.diabet.2021.101297 |
death/ICU, ↓55.5%, p=0.04 |
The association between metformin treatment and COVID-19 outcomes according to metformin continuation during hospitalisation |
|
Details
Retrospective 140 diabetic patients in France, showing lower mortality for patients where metformin use was continued after hospitalization. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| The association between metformin treatment and COVID-19 outcomes according to metformin continuation during hospitalisation |
| Al-Salameh et al., Diabetes & Metabolism, doi:10.1016/j.diabet.2021.101297 |
|
Retrospective 140 diabetic patients in France, showing lower mortality for patients where metformin use was continued after hospitalization.
|
risk of death/ICU, 55.5% lower, RR 0.45, p = 0.04, treatment 9 of 47 (19.1%), control 22 of 50 (44.0%), NNT 4.0, adjusted, OR converted to RR, metformin continued, multivariable.
|
|
risk of death/ICU, 68.4% higher, RR 1.68, p = 0.02, treatment 34 of 43 (79.1%), control 22 of 50 (44.0%), adjusted, OR converted to RR, metformin discontinued, multivariable.
|
![]()
Al-Salameh et al., 11/30/2021, retrospective, France, Europe, peer-reviewed, 4 authors.
|
|
Submit Corrections or Comments
|
|
In Vitro |
Parthasarathy et al., bioRxiv, doi:10.1101/2021.11.18.469078 (Preprint) (In Vitro) |
In Vitro |
Metformin Suppresses SARS-CoV-2 in Cell Culture |
|
Details
In Vitro study showing metformin inhibits SARS-CoV-2 in Caco2 cells. Metformin reduced viral titers by nearly 99%, and by about 90% when cells were treated prior to infection. |
|
Details
Source
PDF
In Vitro
In Vitro
|
| Metformin Suppresses SARS-CoV-2 in Cell Culture |
| Parthasarathy et al., bioRxiv, doi:10.1101/2021.11.18.469078 (Preprint) (In Vitro) |
In Vitro study showing metformin inhibits SARS-CoV-2 in Caco2 cells. Metformin reduced viral titers by nearly 99%, and by about 90% when cells were treated prior to infection.
![]()
Parthasarathy et al., 11/19/2021, preprint, 3 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Bliden et al., Circulation, 144:A12228 (Preprint) |
death, ↓59.8%, p=0.21 |
Metformin Use in Patients Hospitalized With COVID-19: Lower Inflammation, Oxidative Stress, and Thrombotic Risk Markers and Better Clinical Outcomes |
|
Details
Retrospective 75 diabetes patients, 34 on metformin, showing lower mortality with treatment in unadjusted results with minimal group details. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin Use in Patients Hospitalized With COVID-19: Lower Inflammation, Oxidative Stress, and Thrombotic Risk Markers and Better Clinical Outcomes |
| Bliden et al., Circulation, 144:A12228 (Preprint) |
|
Retrospective 75 diabetes patients, 34 on metformin, showing lower mortality with treatment in unadjusted results with minimal group details.
|
risk of death, 59.8% lower, RR 0.40, p = 0.21, treatment 3 of 34 (8.8%), control 9 of 41 (22.0%), NNT 7.6.
|
|
risk of mechanical ventilation, 75.9% lower, RR 0.24, p = 0.05, treatment 2 of 34 (5.9%), control 10 of 41 (24.4%), NNT 5.4.
|
![]()
Excluded in after exclusion results of meta analysis:
unadjusted results with minimal group details.
Bliden et al., 11/8/2021, retrospective, USA, North America, preprint, 9 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Ong et al., Journal of the ASEAN Federation of Endocrine Societies, doi:10.15605/jafes.036.02.20 |
death, ↓46.8%, p=0.02 |
Association Between Metformin Use and Mortality Among Patients with Type 2 Diabetes Mellitus Hospitalized for COVID-19 Infection |
|
Details
Retrospective 355 diabetic hospitalized COVID-19 patients in the Philippines, showing lower mortality with metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Association Between Metformin Use and Mortality Among Patients with Type 2 Diabetes Mellitus Hospitalized for COVID-19 Infection |
| Ong et al., Journal of the ASEAN Federation of Endocrine Societies, doi:10.15605/jafes.036.02.20 |
|
Retrospective 355 diabetic hospitalized COVID-19 patients in the Philippines, showing lower mortality with metformin use.
|
risk of death, 46.8% lower, RR 0.53, p = 0.02, treatment 33 of 186 (17.7%), control 57 of 169 (33.7%), NNT 6.3, adjusted, OR converted to RR, combined pre-existing and in-hospital use.
|
|
risk of death, 23.9% lower, RR 0.76, p = 0.16, treatment 28 of 109 (25.7%), control 57 of 169 (33.7%), NNT 12, OR converted to RR, pre-existing use, unadjusted.
|
|
risk of death, 85.2% lower, RR 0.15, p = 0.002, treatment 2 of 40 (5.0%), control 57 of 169 (33.7%), NNT 3.5, OR converted to RR, in-hospital use, unadjusted.
|
|
risk of death, 76.0% lower, RR 0.24, p = 0.005, treatment 3 of 37 (8.1%), control 57 of 169 (33.7%), NNT 3.9, OR converted to RR, mixed pre-existing/in-hospital use, unadjusted.
|
![]()
Ong et al., 10/30/2021, retrospective, Philippines, Asia, peer-reviewed, 6 authors, study period 1 March, 2020 - 30 September, 2020.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Saygili et al., Irish Journal of Medical Science, doi:10.1007/s11845-021-02823-9 |
death, ↓41.5%, p=0.02 |
Preadmission usage of metformin and mortality in COVID-19 patients including the post-discharge period |
|
Details
Retrospective 586 diabetic hospitalized COVID-19 patients in Turkey, showing lower mortality with existing metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Preadmission usage of metformin and mortality in COVID-19 patients including the post-discharge period |
| Saygili et al., Irish Journal of Medical Science, doi:10.1007/s11845-021-02823-9 |
|
Retrospective 586 diabetic hospitalized COVID-19 patients in Turkey, showing lower mortality with existing metformin use.
|
risk of death, 41.5% lower, RR 0.58, p = 0.02, treatment 120, control 120, overall mortality, Cox regression in matched group, propensity score matching.
|
![]()
Saygili et al., 10/29/2021, retrospective, Turkey, Europe, peer-reviewed, 5 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Wander et al., Diabetes Care, doi:10.2337/dc21-1351 |
death, ↓15.0%, p<0.0001 |
Prior Glucose-Lowering Medication Use and 30-Day Outcomes Among 64,892 Veterans With Diabetes and COVID-19 |
|
Details
Retrospective 64,892 veterans with diabetes in the USA, showing lower mortality with existing metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Prior Glucose-Lowering Medication Use and 30-Day Outcomes Among 64,892 Veterans With Diabetes and COVID-19 |
| Wander et al., Diabetes Care, doi:10.2337/dc21-1351 |
|
Retrospective 64,892 veterans with diabetes in the USA, showing lower mortality with existing metformin use.
|
risk of death, 15.0% lower, RR 0.85, p < 0.001, treatment 29,685, control 35,207, OR converted to RR, logistic regression, within 30 days of diagnosis, control prevalance approximated with overall prevalence.
|
|
risk of ICU admission, 1.9% lower, RR 0.98, p = 0.62, treatment 29,685, control 35,207, OR converted to RR, logistic regression, within 30 days of diagnosis, control prevalance approximated with overall prevalence.
|
|
risk of hospitalization, 3.2% lower, RR 0.97, p = 0.09, treatment 29,685, control 35,207, OR converted to RR, logistic regression, within 30 days of diagnosis, control prevalance approximated with overall prevalence.
|
![]()
Wander et al., 10/6/2021, retrospective, database analysis, USA, North America, peer-reviewed, 8 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Ando et al., Scientific Reports, doi:10.1038/s41598-021-96720-x |
hosp., ↓39.0%, p=0.04 |
Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States |
|
Details
Retrospective 28,093 COVID+ patients in the USA, showing lower risk of hospitalization with metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States |
| Ando et al., Scientific Reports, doi:10.1038/s41598-021-96720-x |
|
Retrospective 28,093 COVID+ patients in the USA, showing lower risk of hospitalization with metformin use.
|
risk of hospitalization, 39.0% lower, HR 0.61, p = 0.04, treatment 19 of 663 (2.9%), control 1,056 of 27,430 (3.8%), adjusted, multivariable, Cox proportional hazards.
|
![]()
Ando et al., 9/9/2021, retrospective, USA, North America, peer-reviewed, 6 authors, study period 1 January, 2020 - 30 November, 2020.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Wang et al., BMJ Open Diabetes Research & Care, doi:10.1136/bmjdrc-2021-002299 |
ICU, ↓12.0%, p=0.005 |
Evaluation and management of COVID-19-related severity in people with type 2 diabetes |
|
Details
Retrospective 16,504 COVID-19 type 2 diabetes patients, showing lower risk of ICU admission with existing metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Evaluation and management of COVID-19-related severity in people with type 2 diabetes |
| Wang et al., BMJ Open Diabetes Research & Care, doi:10.1136/bmjdrc-2021-002299 |
|
Retrospective 16,504 COVID-19 type 2 diabetes patients, showing lower risk of ICU admission with existing metformin use.
|
risk of ICU admission, 12.0% lower, RR 0.88, p = 0.005, treatment 6,504, control 10,000, Cox proportional hazards.
|
![]()
Wang et al., 9/7/2021, retrospective, USA, North America, peer-reviewed, 4 authors.
|
|
Submit Corrections or Comments
|
|
Meta |
Yang et al., Diabetes Research and Clinical Practice, doi:10.1016/j.diabres.2021.108977 (meta analysis) |
death, ↓36.0%, p<0.0001 |
The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus |
|
Details
Meta analysis of 17 studies including 20,719 COVID-19 patients with diabetes, showing lower risk of mortality and severity with metformin. |
|
Details
Source
PDF
Meta
Meta
|
| The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus |
| Yang et al., Diabetes Research and Clinical Practice, doi:10.1016/j.diabres.2021.108977 (meta analysis) |
|
Meta analysis of 17 studies including 20,719 COVID-19 patients with diabetes, showing lower risk of mortality and severity with metformin.
|
risk of death, 36.0% lower, OR 0.64, p < 0.001, RR approximated with OR.
|
![]()
Yang et al., 8/31/2021, peer-reviewed, 4 authors.
|
|
Submit Corrections or Comments
|
|
Early |
Reis et al., The Lancet Regional Health - Americas, doi:10.1016/j.lana.2021.100142 (preprint 8/31/21) |
death, ↓26.6%, p=0.53 |
Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial |
|
Details
RCT with 215 patients treated with metformin and 203 controls, showing no significant difference with treatment. The hospitalization risk for off-protocol patients was several times higher in both arms, resulting in Simpson's paradox when.. |
|
Details
Source
PDF
Early treatment study
Early treatment study
|
| Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial |
| Reis et al., The Lancet Regional Health - Americas, doi:10.1016/j.lana.2021.100142 (preprint 8/31/21) |
|
RCT with 215 patients treated with metformin and 203 controls, showing no significant difference with treatment.The hospitalization risk for off-protocol patients was several times higher in both arms, resulting in Simpson's paradox when combining per-protocol and off-protocol patients [].750mg twice daily for 10 days. NCT04727424.
|
risk of death, 26.6% lower, RR 0.73, p = 0.53, treatment 7 of 215 (3.3%), control 9 of 203 (4.4%), NNT 85, day 28.
|
|
risk of hospitalization, 5.6% lower, RR 0.94, p = 0.88, treatment 24 of 215 (11.2%), control 24 of 203 (11.8%), NNT 152, ITT.
|
|
risk of hospitalization, 39.1% lower, RR 0.61, p = 0.28, treatment 8 of 168 (4.8%), control 14 of 179 (7.8%), NNT 33, PP.
|
|
risk of extended ER observation or hospitalization, 14.0% higher, RR 1.14, p = 0.58, treatment 34 of 215 (15.8%), control 28 of 203 (13.8%), ITT, primary outcome.
|
|
risk of extended ER observation or hospitalization, 12.0% lower, RR 0.88, p = 0.72, treatment 14 of 168 (8.3%), control 17 of 179 (9.5%), NNT 86, PP.
|
|
risk of ER visit, 31.0% lower, RR 0.69, p = 0.48, treatment 8 of 216 (3.7%), control 11 of 205 (5.4%), NNT 60, ITT.
|
|
risk of ER visit, 25.9% lower, RR 0.74, p = 0.62, treatment 7 of 171 (4.1%), control 10 of 181 (5.5%), NNT 70, PP.
|
|
risk of no viral clearance, 1.0% lower, RR 0.99, p = 0.85, treatment 215, control 203, adjusted.
|
![]()
Reis et al., 8/31/2021, Double Blind Randomized Controlled Trial, Brazil, South America, peer-reviewed, 23 authors, trial NCT04727424 (TOGETHER). |
|
Submit Corrections or Comments
|
|
PrEPPEP |
Cheng et al., Cell Metabolism, doi:10.1016/j.cmet.2020.08.013 |
death, ↑65.0%, p=0.25 |
Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes |
|
Details
Retrospective 1,213 hospitalized diabetic COVID-19 patients in China, showing no significant difference in mortality with pre-existing metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes |
| Cheng et al., Cell Metabolism, doi:10.1016/j.cmet.2020.08.013 |
|
Retrospective 1,213 hospitalized diabetic COVID-19 patients in China, showing no significant difference in mortality with pre-existing metformin use.
|
risk of death, 65.0% higher, HR 1.65, p = 0.25, treatment 678, control 535, after PSM.
|
![]()
Cheng et al., 8/20/2021, retrospective, propensity score matching, China, Asia, peer-reviewed, 35 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Boye et al., Diabetes Therapy, doi:10.1007/s13300-021-01110-1 |
hosp., ↓10.0%, p<0.0001 |
Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States |
|
Details
Retrospective 9531 COVID+ diabetes patients in the USA, showing lower risk of hospitalization with existing biguanides treatment (defined as mainly metformin in the abstract and entirely metformin in the text). |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States |
| Boye et al., Diabetes Therapy, doi:10.1007/s13300-021-01110-1 |
|
Retrospective 9531 COVID+ diabetes patients in the USA, showing lower risk of hospitalization with existing biguanides treatment (defined as mainly metformin in the abstract and entirely metformin in the text).
|
risk of hospitalization, 10.0% lower, RR 0.90, p < 0.001, treatment 2,067 of 4,250 (48.6%), control 3,196 of 5,281 (60.5%), NNT 8.4, OR converted to RR.
|
![]()
Boye et al., 7/18/2021, retrospective, USA, North America, peer-reviewed, 14 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Blanc et al., GeroScience, doi:10.1007/s11357-021-00397-z |
death, ↓78.6%, p=0.06 |
Therapeutic prevention of COVID-19 in elderly: a case–control study |
|
Details
Retrospective 179 patients in France exposed to COVID-19 showing, without statistical significance, a higher risk of cases, and a lower risk of mortality among cases with existing metformin treatment. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Therapeutic prevention of COVID-19 in elderly: a case–control study |
| Blanc et al., GeroScience, doi:10.1007/s11357-021-00397-z |
|
Retrospective 179 patients in France exposed to COVID-19 showing, without statistical significance, a higher risk of cases, and a lower risk of mortality among cases with existing metformin treatment.
|
risk of death, 78.6% lower, RR 0.21, p = 0.06, treatment 1 of 14 (7.1%), control 25 of 75 (33.3%), NNT 3.8, COVID+.
|
|
risk of case, 43.7% higher, RR 1.44, p = 0.12, treatment 11 of 16 (68.8%), control 78 of 163 (47.9%).
|
![]()
Blanc et al., 7/17/2021, retrospective, France, Europe, peer-reviewed, 22 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Tamura et al., Diabetology & Metabolic Syndrome, doi:10.1186/s13098-021-00695-8 |
death, ↓96.6%, p=0.02 |
Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies |
|
Details
Retrospective 188 hospitalized patients in Brazil, showing lower risk of mortality with metformin use. Authors note that, although pre-hospital metformin use improved clinical parameters at admission, continuous use during hospitalization.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies |
| Tamura et al., Diabetology & Metabolic Syndrome, doi:10.1186/s13098-021-00695-8 |
|
Retrospective 188 hospitalized patients in Brazil, showing lower risk of mortality with metformin use. Authors note that, although pre-hospital metformin use improved clinical parameters at admission, continuous use during hospitalization is essential. Patients that used pre-hospital metformin therapy but interrupted the treatment during hospitalization showed higher mortality than those that continued metformin therapy.
|
risk of death, 96.6% lower, OR 0.03, p = 0.02, treatment 115, control 73, adjusted, in-hospital use, multivariable, RR approximated with OR.
|
![]()
Tamura et al., 7/13/2021, retrospective, Brazil, South America, peer-reviewed, 4 authors, study period 10 March, 2020 - 13 November, 2020.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Ravindra et al., medRxiv, doi:10.1101/2021.04.20.21255792 |
death, ↓29.6%, p=0.42 |
Retrospective Assessment of Treatments of Hospitalized Covid-19 Patients |
|
Details
Retrospective 1,035 hospitalized patients in India. Of 366 diabetic patients, there was lower mortality for the 53 that were on metformin. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Retrospective Assessment of Treatments of Hospitalized Covid-19 Patients |
| Ravindra et al., medRxiv, doi:10.1101/2021.04.20.21255792 |
|
Retrospective 1,035 hospitalized patients in India. Of 366 diabetic patients, there was lower mortality for the 53 that were on metformin.
|
risk of death, 29.6% lower, RR 0.70, p = 0.42, treatment 5 of 53 (9.4%), control 57 of 313 (18.2%), adjusted, OR converted to RR.
|
![]()
Excluded in after exclusion results of meta analysis:
minimal details provided.
Ravindra et al., 5/5/2021, retrospective, India, South Asia, peer-reviewed, 14 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Alamgir et al., medRxiv, doi:10.1101/2021.03.22.21254110 (Preprint) |
death, ↓27.0%, p<0.0001 |
Drug repositioning candidates identified using in-silico quasi-quantum molecular simulation demonstrate reduced COVID-19 mortality in 1.5M patient records |
|
Details
In Silico study followed by PSM analysis of the National COVID Cohort Collaborative data in the USA, showing 27% lower mortality with metformin use. ABSTRACTBackgroundDru.. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Drug repositioning candidates identified using in-silico quasi-quantum molecular simulation demonstrate reduced COVID-19 mortality in 1.5M patient records |
| Alamgir et al., medRxiv, doi:10.1101/2021.03.22.21254110 (Preprint) |
|
In Silico study followed by PSM analysis of the National COVID Cohort Collaborative data in the USA, showing 27% lower mortality with metformin use.ABSTRACTBackgroundDrug repositioning is a key component of COVID-19 pandemic response, through identification of existing drugs that can effectively disrupt COVID-19 disease processes, contributing valuable insights into disease pathways. Traditional non in silico drug repositioning approaches take substantial time and cost to discover effect and, crucially, to validate repositioned effects.MethodsUsing a novel in-silico quasi-quantum molecular simulation platform that analyzes energies and electron densities of both target proteins and candidate interruption compounds on High Performance Computing (HPC), we identified a list of FDA-approved compounds with potential to interrupt specific SARS-CoV-2 proteins. Subsequently we used 1.5M patient records from the National COVID Cohort Collaborative to create matched cohorts to refine our in-silico hits to those candidates that show statistically significant clinical effect.ResultsWe identified four drugs, Metformin, Triamcinolone, Amoxicillin and Hydrochlorothiazide, that were associated with reduced mortality by 27%, 26%, 26%, and 23%, respectively, in COVID-19 patients.ConclusionsTogether, these findings provide support to our hypothesis that in-silico simulation of active compounds against SARS-CoV-2 proteins followed by statistical analysis of electronic health data results in effective therapeutics identification.
|
risk of death, 27.0% lower, OR 0.73, p < 0.001, treatment 11,062, control 11,062, all patients, RR approximated with OR.
|
|
risk of death, 34.0% lower, OR 0.66, p = 0.007, treatment 5,369, control 5,369, diabetic patients with CCI≤3, RR approximated with OR.
|
|
risk of death, 30.0% lower, OR 0.70, p = 0.02, treatment 2,525, control 2,525, non-diabetic patients with CCI≤3, RR approximated with OR.
|
![]()
Alamgir et al., 4/6/2021, retrospective, database analysis, USA, North America, preprint, 11 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Ghany et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2021.02.022 |
death, ↓66.0%, p=0.0002 |
Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA |
|
Details
Retrospective 1,139 elderly COVID+ patients in the USA, 392 with pre-existing metformin use, showing significantly lower mortality, hospitalization, and ARDS with treatment. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA |
| Ghany et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2021.02.022 |
|
Retrospective 1,139 elderly COVID+ patients in the USA, 392 with pre-existing metformin use, showing significantly lower mortality, hospitalization, and ARDS with treatment.
|
risk of death, 66.0% lower, HR 0.34, p < 0.001, treatment 392, control 747, adjusted, multivariable, Cox proportional hazards.
|
|
risk of hospitalization, 29.0% lower, HR 0.71, p = 0.008, treatment 392, control 747, adjusted, multivariable, Cox proportional hazards.
|
|
risk of ARDS, 68.0% lower, HR 0.32, p < 0.001, treatment 392, control 747, adjusted, multivariable, Cox proportional hazards.
|
![]()
Ghany et al., 3/31/2021, retrospective, USA, North America, peer-reviewed, 8 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Jiang et al., Diabetes Research and Clinical Practice, doi:10.1016/j.diabres.2020.108619 |
death, ↓46.0%, p=0.40 |
Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study |
|
Details
Retrospective 328 COVID-19 patients with type 2 diabetes in China, showing significantly lower risk of ARDS with existing metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study |
| Jiang et al., Diabetes Research and Clinical Practice, doi:10.1016/j.diabres.2020.108619 |
|
Retrospective 328 COVID-19 patients with type 2 diabetes in China, showing significantly lower risk of ARDS with existing metformin use.
|
risk of death, 46.0% lower, HR 0.54, p = 0.40, treatment 3 of 74 (4.1%), control 10 of 74 (13.5%), adjusted, mixed effect Cox, propensity score matching.
|
|
risk of ARDS, 80.2% lower, RR 0.20, p = 0.02, treatment 8 of 74 (10.8%), control 17 of 74 (23.0%), NNT 8.2, adjusted, OR converted to RR, mixed effect Cox, propensity score matching.
|
![]()
Jiang et al., 3/31/2021, retrospective, China, Asia, peer-reviewed, 12 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Khunti et al., The Lacent Diabetes & Endocrinology, doi:10.1016/S2213-8587(21)00050-4 |
death, ↓23.0%, p<0.0001 |
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England |
|
Details
Retrospective 2,851,465 people with type 2 diabetes in the UK, showing lower mortality with existing metformin use. Results are subject to confounding by indication because metformin is typically used early in the progression of type 2 di.. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England |
| Khunti et al., The Lacent Diabetes & Endocrinology, doi:10.1016/S2213-8587(21)00050-4 |
|
Retrospective 2,851,465 people with type 2 diabetes in the UK, showing lower mortality with existing metformin use. Results are subject to confounding by indication because metformin is typically used early in the progression of type 2 diabetes.
|
risk of death, 23.0% lower, HR 0.77, p < 0.001, adjusted.
|
![]()
Khunti et al., 3/30/2021, retrospective, population-based cohort, United Kingdom, Europe, peer-reviewed, 15 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Holt et al., Thorax, doi:10.1136/thoraxjnl-2021-217487 |
cases, ↑27.0%, p=0.42 |
Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK) |
|
Details
Prospective survey-based study with 15,227 people in the UK, showing lower risk of COVID-19 cases with vitamin A, vitamin D, zinc, selenium, probiotics, and inhaled corticosteroids; and higher risk with metformin and vitamin C. Statistica.. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK) |
| Holt et al., Thorax, doi:10.1136/thoraxjnl-2021-217487 |
|
Prospective survey-based study with 15,227 people in the UK, showing lower risk of COVID-19 cases with vitamin A, vitamin D, zinc, selenium, probiotics, and inhaled corticosteroids; and higher risk with metformin and vitamin C. Statistical significance was not reached for any of these. Except for vitamin D, the results for treatments we follow were only adjusted for age, sex, duration of participation, and test frequency. NCT04330599. COVIDENCE UK.
|
risk of case, 27.0% higher, RR 1.27, p = 0.42, treatment 12 of 429 (2.8%), control 434 of 14,798 (2.9%), adjusted, OR converted to RR, minimally adjusted, group sizes approximated.
|
![]()
Excluded in after exclusion results of meta analysis:
significant unadjusted confounding possible.
Holt et al., 3/30/2021, prospective, United Kingdom, Europe, peer-reviewed, 34 authors, study period 1 May, 2020 - 5 February, 2021, trial NCT04330599. |
|
Submit Corrections or Comments
|
|
PrEPPEP |
Wargny et al., Diabetologia, doi:10.1007/s00125-020-05351-w |
death, ↓28.3%, p=0.03 |
Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study |
|
Details
Retrospective 2,796 hospitalized diabetes patients with COVID-19 in France, showing lower mortality with metformin use. CORONADO. NCT04324736. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study |
| Wargny et al., Diabetologia, doi:10.1007/s00125-020-05351-w |
|
Retrospective 2,796 hospitalized diabetes patients with COVID-19 in France, showing lower mortality with metformin use. CORONADO. NCT04324736.
|
risk of death, 28.3% lower, RR 0.72, p = 0.03, treatment 247 of 1,553 (15.9%), control 330 of 1,241 (26.6%), NNT 9.4, adjusted, OR converted to RR, multivariable, day 28.
|
|
risk of no hospital discharge, 14.8% lower, RR 0.85, p = 0.02, treatment 690 of 1,553 (44.4%), control 702 of 1,241 (56.6%), NNT 8.2, adjusted, OR converted to RR, multivariable, day 28.
|
![]()
Wargny et al., 2/17/2021, retrospective, France, Europe, peer-reviewed, 43 authors, study period 10 March, 2020 - 10 April, 2020, trial NCT04324736. |
|
Submit Corrections or Comments
|
|
PrEPPEP |
Oh et al., Acta Diabetologica, doi:10.1007/s00592-020-01666-7 |
death, ↑26.0%, p=0.30 |
Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study |
|
Details
Retrospective 27,493 type II diabetes patients in the USA, 7,204 on metformin, showing significantly lower COVID-19 cases, but no significant difference in mortality. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study |
| Oh et al., Acta Diabetologica, doi:10.1007/s00592-020-01666-7 |
|
Retrospective 27,493 type II diabetes patients in the USA, 7,204 on metformin, showing significantly lower COVID-19 cases, but no significant difference in mortality.
|
risk of death, 26.0% higher, OR 1.26, p = 0.30, treatment 5,946, control 5,946, adjusted, multivariable, RR approximated with OR.
|
|
risk of case, 28.0% lower, RR 0.72, p < 0.001, treatment 390 of 5,946 (6.6%), control 541 of 5,946 (9.1%), NNT 39, adjusted, OR converted to RR, propensity score matching.
|
![]()
Oh et al., 2/13/2021, retrospective, USA, North America, peer-reviewed, 2 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Lally et al., Journal of the American Medical Directors Association, doi:10.1016/j.jamda.2020.10.031 |
death, ↓52.0%, p=0.009 |
Metformin is Associated with Decreased 30-Day Mortality Among Nursing Home Residents Infected with SARS-CoV2 |
|
Details
Retrospective 775 nursing home residents in the USA, showing lower mortality with existing metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin is Associated with Decreased 30-Day Mortality Among Nursing Home Residents Infected with SARS-CoV2 |
| Lally et al., Journal of the American Medical Directors Association, doi:10.1016/j.jamda.2020.10.031 |
|
Retrospective 775 nursing home residents in the USA, showing lower mortality with existing metformin use.
|
risk of death, 52.0% lower, HR 0.48, p = 0.009, treatment 16 of 127 (12.6%), control 144 of 648 (22.2%), NNT 10, adjusted, multivariable regression.
|
![]()
Lally et al., 1/31/2021, retrospective, USA, North America, peer-reviewed, 6 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Crouse et al., Front. Endocrinol., doi:10.3389/fendo.2020.600439 |
death, ↓60.8%, p=0.02 |
Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes |
|
Details
Retrospective 219 COVID-19+ diabetes patients in the USA, showing lower mortality with existing metformin treatment. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes |
| Crouse et al., Front. Endocrinol., doi:10.3389/fendo.2020.600439 |
|
Retrospective 219 COVID-19+ diabetes patients in the USA, showing lower mortality with existing metformin treatment.
|
risk of death, 60.8% lower, RR 0.39, p = 0.02, treatment 8 of 76 (10.5%), control 34 of 144 (23.6%), NNT 7.6, adjusted, OR converted to RR, multiple logistic regression.
|
![]()
Crouse et al., 1/13/2021, retrospective, USA, North America, peer-reviewed, 6 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Huh et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.12.041 |
progression, ↑1.0%, p=0.11 |
Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea |
|
Details
Retrospective database analysis showing no significant differences with pre-existing metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea |
| Huh et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.12.041 |
|
Retrospective database analysis showing no significant differences with pre-existing metformin use.
|
risk of progression, 1.0% higher, RR 1.01, p = 0.11, treatment 104 of 272 (38.2%), control 774 of 2,533 (30.6%), adjusted, multivariable.
|
|
risk of case, 4.0% lower, RR 0.96, p = 0.82, treatment 329 of 1,874 (17.6%), control 7,012 of 42,172 (16.6%), adjusted, multivariable.
|
![]()
Huh et al., 12/19/2020, retrospective, database analysis, South Korea, Asia, peer-reviewed, 8 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Lalau et al., Diabetes & Metabolism, doi:10.1016/j.diabet.2020.101216 |
death, ↓22.2%, p=0.16 |
Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19 |
|
Details
Retrospective 2,449 hospitalized COVID-19 diabetes patients in France, 1,496 with existing metformin use, showing lower mortality with treatment. Statistical significance was reached in model 1 but not in models 2-4 which also adjust for .. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19 |
| Lalau et al., Diabetes & Metabolism, doi:10.1016/j.diabet.2020.101216 |
|
Retrospective 2,449 hospitalized COVID-19 diabetes patients in France, 1,496 with existing metformin use, showing lower mortality with treatment. Statistical significance was reached in model 1 but not in models 2-4 which also adjust for HbA1c, eGFR, and diabetes duration, but have a lower number of patients. CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes).
|
risk of death, 22.2% lower, OR 0.78, p = 0.16, treatment 671, control 419, day 28, model 2, propensity score matching, RR approximated with OR.
|
|
risk of death/intubation, 17.8% lower, OR 0.82, p = 0.21, treatment 671, control 419, day 28, model 2, propensity score matching, primary outcome, RR approximated with OR.
|
|
risk of mechanical ventilation, 6.8% lower, OR 0.93, p = 0.72, treatment 671, control 419, day 28, model 2, propensity score matching, RR approximated with OR.
|
![]()
Lalau et al., 12/10/2020, retrospective, France, Europe, peer-reviewed, 33 authors, study period 10 March, 2020 - 10 April, 2020.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Bramante et al., The Lancet Healthy Longevity, doi:10.1016/S2666-7568(20)30033-7 |
death, ↓7.2%, p=0.15 |
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis |
|
Details
Retrospective 6,256 COVID-19+ diabetes patients in the USA, showing lower mortality with existing metformin treatment, statistically significant only for women. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis |
| Bramante et al., The Lancet Healthy Longevity, doi:10.1016/S2666-7568(20)30033-7 |
|
Retrospective 6,256 COVID-19+ diabetes patients in the USA, showing lower mortality with existing metformin treatment, statistically significant only for women.
|
risk of death, 7.2% lower, RR 0.93, p = 0.15, treatment 394 of 2,333 (16.9%), control 791 of 3,923 (20.2%), NNT 31, OR converted to RR, PSM, all patients.
|
|
risk of death, 24.1% lower, OR 0.76, p = 0.02, treatment 1,129, control 2,173, PSM, women, RR approximated with OR.
|
|
risk of death, 3.5% higher, OR 1.03, p = 0.75, treatment 1,204, control 1,750, PSM, men, RR approximated with OR.
|
![]()
Bramante et al., 12/3/2020, retrospective, database analysis, USA, North America, peer-reviewed, 17 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Pérez-Belmonte et al., BMC Medicine, doi:10.1186/s12916-020-01832-2 |
death, ↑10.4%, p=0.48 |
Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study |
|
Details
Retrospective 2,666 type 2 diabetes COVID-19 patients in Spain, showing higher mortality with existing metformin use (not statistically significant). |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study |
| Pérez-Belmonte et al., BMC Medicine, doi:10.1186/s12916-020-01832-2 |
|
Retrospective 2,666 type 2 diabetes COVID-19 patients in Spain, showing higher mortality with existing metformin use (not statistically significant).
|
risk of death, 10.4% higher, RR 1.10, p = 0.48, treatment 79 of 249 (31.7%), control 79 of 249 (31.7%), OR converted to RR, mixed effect logistic regression, propensity score matching.
|
![]()
Pérez-Belmonte et al., 11/16/2020, retrospective, propensity score matching, Spain, Europe, peer-reviewed, 26 authors.
|
|
Submit Corrections or Comments
|
|
Meta |
Lukito et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2020.11.006 (meta analysis) |
meta-analysis |
The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis |
|
Details
Meta analysis of 9 studies showing lower mortality with metformin use. |
|
Details
Source
PDF
Meta
Meta
|
| The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis |
| Lukito et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2020.11.006 (meta analysis) |
Meta analysis of 9 studies showing lower mortality with metformin use.
![]()
Lukito et al., 11/11/2020, peer-reviewed, 6 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Gao et al., Clinical and Translational Science, doi:10.1111/cts.12897 |
progression, ↑225.0%, p=0.045 |
Risk of Metformin in Patients With Type 2 Diabetes With COVID‐19: A Preliminary Retrospective Report |
|
Details
Retrospective 110 hospitalized COVID-19 patients with diabetes in China, showing increased risk of severity with metformin. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Risk of Metformin in Patients With Type 2 Diabetes With COVID‐19: A Preliminary Retrospective Report |
| Gao et al., Clinical and Translational Science, doi:10.1111/cts.12897 |
|
Retrospective 110 hospitalized COVID-19 patients with diabetes in China, showing increased risk of severity with metformin.
|
risk of progression, 225.0% higher, RR 3.25, p = 0.045, treatment 16 of 56 (28.6%), control 4 of 54 (7.4%), OR converted to RR, progression to life threatening complications.
|
![]()
Gao et al., 10/19/2020, retrospective, China, Asia, peer-reviewed, 7 authors, study period 31 January, 2020 - 20 March, 2020.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Goodall et al., Epidemiology and Infection, doi:10.1017/S0950268820002472 |
death, ↓3.0%, p=0.81 |
Risk factors for severe disease in patients admitted with COVID-19 to a hospital in London, England: a retrospective cohort study |
|
Details
Retrospective 981 hospitalized patients in the UK, showing no significant difference with metformin use. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Risk factors for severe disease in patients admitted with COVID-19 to a hospital in London, England: a retrospective cohort study |
| Goodall et al., Epidemiology and Infection, doi:10.1017/S0950268820002472 |
|
Retrospective 981 hospitalized patients in the UK, showing no significant difference with metformin use.
|
risk of death, 3.0% lower, HR 0.97, p = 0.81, treatment 74 of 210 (35.2%), control 280 of 771 (36.3%), NNT 93.
|
![]()
Goodall et al., 10/13/2020, retrospective, United Kingdom, Europe, peer-reviewed, 7 authors, study period 12 March, 2020 - 15 April, 2020.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Li et al., Endocrine Practice, doi:10.4158/EP-2020-0466 |
death, ↓77.7%, p=0.02 |
Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19 |
|
Details
Retrospective 131 type II diabetes patients with COVID pneumonia, showing lower mortality with existing metformin use. Acarbose (commonly used in China as an initial therapy for diabetes) did not have a similar association with mortality,.. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19 |
| Li et al., Endocrine Practice, doi:10.4158/EP-2020-0466 |
|
Retrospective 131 type II diabetes patients with COVID pneumonia, showing lower mortality with existing metformin use. Acarbose (commonly used in China as an initial therapy for diabetes) did not have a similar association with mortality, suggesting that the result may not be explained by metformin being used early in type II diabetes.
|
risk of death, 77.7% lower, HR 0.22, p = 0.02, treatment 2 of 37 (5.4%), control 21 of 94 (22.3%), NNT 5.9, adjusted, multivariable.
|
|
risk of mechanical ventilation, 27.0% higher, RR 1.27, p = 1.00, treatment 1 of 37 (2.7%), control 2 of 94 (2.1%).
|
![]()
Li et al., 10/1/2020, retrospective, China, Asia, peer-reviewed, 16 authors, study period 23 January, 2020 - 19 March, 2020.
|
|
Submit Corrections or Comments
|
|
Meta |
Kow et al., Journal of Medical Virology, doi:10.1002/jmv.26498 (meta analysis) |
meta-analysis |
Mortality risk with preadmission metformin use in patients with COVID‐19 and diabetes: A meta‐analysis |
|
Details
Meta analysis of 5 studies showing lower mortality with metformin use. |
|
Details
Source
PDF
Meta
Meta
|
| Mortality risk with preadmission metformin use in patients with COVID‐19 and diabetes: A meta‐analysis |
| Kow et al., Journal of Medical Virology, doi:10.1002/jmv.26498 (meta analysis) |
Meta analysis of 5 studies showing lower mortality with metformin use.
![]()
Kow et al., 9/30/2020, peer-reviewed, 2 authors.
|
|
Submit Corrections or Comments
|
|
Meta |
Hariyanto et al., Obesity Medicine, doi:10.1016/j.obmed.2020.100290 (meta analysis) |
meta-analysis |
Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection |
|
Details
Meta analysis of 5 studies showing lower mortality with metformin use. |
|
Details
Source
PDF
Meta
Meta
|
| Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection |
| Hariyanto et al., Obesity Medicine, doi:10.1016/j.obmed.2020.100290 (meta analysis) |
Meta analysis of 5 studies showing lower mortality with metformin use.
![]()
Hariyanto et al., 8/18/2020, peer-reviewed, 2 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Kim et al., Diabetes & Metabolism Journal, doi:10.4093/dmj.2020.0146 |
death, ↓64.0%, p=0.10 |
The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea |
|
Details
Retrospective 235 hospitalized diabetes patients in South Korea, showing lower mortality and lower progression to severe disease with metformin. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea |
| Kim et al., Diabetes & Metabolism Journal, doi:10.4093/dmj.2020.0146 |
|
Retrospective 235 hospitalized diabetes patients in South Korea, showing lower mortality and lower progression to severe disease with metformin.
|
risk of death, 64.0% lower, OR 0.36, p = 0.10, treatment 113, control 122, adjusted, multivariable, RR approximated with OR.
|
|
risk of progression, 52.0% lower, OR 0.48, p = 0.13, treatment 113, control 122, adjusted, multivariable, RR approximated with OR.
|
![]()
Kim et al., 8/12/2020, retrospective, South Korea, Asia, peer-reviewed, 32 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Chen et al., Diabetes Care, doi:10.2337/dc20-0660 |
death, ↓33.0%, p=0.46 |
Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication |
|
Details
Retrospective 120 COVID-19 diabetes patients, showing non-statistically significantly lower mortality with existing metformin treatment. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication |
| Chen et al., Diabetes Care, doi:10.2337/dc20-0660 |
|
Retrospective 120 COVID-19 diabetes patients, showing non-statistically significantly lower mortality with existing metformin treatment.
|
risk of death, 33.0% lower, RR 0.67, p = 0.46, treatment 4 of 43 (9.3%), control 15 of 77 (19.5%), NNT 9.8, adjusted, OR converted to RR.
|
![]()
Chen et al., 7/31/2020, retrospective, China, Asia, peer-reviewed, 12 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Wang et al., Journal of Hematology & Oncology, doi:10.1186/s13045-020-00934-x |
death, ↓57.7%, p=0.43 |
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward |
|
Details
Retrospective 58 multiple myeloma COVID-19 patients in the USA, showing non-statistically significant lower mortality with metformin treatment. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward |
| Wang et al., Journal of Hematology & Oncology, doi:10.1186/s13045-020-00934-x |
|
Retrospective 58 multiple myeloma COVID-19 patients in the USA, showing non-statistically significant lower mortality with metformin treatment.
|
risk of death, 57.7% lower, RR 0.42, p = 0.43, treatment 1 of 9 (11.1%), control 13 of 49 (26.5%), NNT 6.5, OR converted to RR.
|
![]()
Wang et al., 7/14/2020, retrospective, USA, North America, peer-reviewed, 13 authors.
|
|
Submit Corrections or Comments
|
|
PrEPPEP |
Luo et al., The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.20-0375 |
death, ↓74.7%, p=0.02 |
Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis |
|
Details
Retrospective 283 COVID-19+ diabetes patients in China, showing lower mortality with existing metformin treatment. |
|
Details
Source
PDF
Prophylaxis study
Prophylaxis study
|
| Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis |
| Luo et al., The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.20-0375 |
|
Retrospective 283 COVID-19+ diabetes patients in China, showing lower mortality with existing metformin treatment.
|
risk of death, 74.7% lower, RR 0.25, p = 0.02, treatment 3 of 104 (2.9%), control 22 of 179 (12.3%), NNT 11, adjusted, OR converted to RR, multivariate.
|
![]()
Luo et al., 5/21/2020, retrospective, China, Asia, peer-reviewed, 9 authors.
|
|
Submit Corrections or Comments
|
